HER2 (Human Epidermal Growth Factor Receptor 2) is a critical biomarker and therapeutic target in breast, gastric, and ovarian cancers. While antibodies (like trastuzumab) have transformed HER2-positive cancer treatment, challenges remain:
Diagnostics developers, CROs, and oncology biotech companies require fast, reliable HER2-binding aptamers for next-generation biosensors, drug delivery systems, and therapeutic platforms.